Who
Jason Duncan
Officer
Company insider
Files Form 4 as: Chief Legal Officer, Neumora Therapeutics; Chief Legal Officer and GC, Albireo Pharma.
In numbers
- Trades disclosed
- 71
- Buys
- 0
- Sells
- 24
- Bought
- $0
- Sold
- $1.0M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 8 Jun 2018
- Last trade
- 20 Aug 2026
- Last filed
- 21 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Aug 2026filed 21 Aug 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —375,000 at $0.00 | filing |
| 20 Aug 2026filed 21 Aug 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —375,000 at $0.00 | filing |
| 8 Jan 2026filed 9 Jan 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 8 Jan 2026filed 9 Jan 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —400,000 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —500,000 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 | filing |
| 13 Feb 2025filed 18 Feb 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —400,000 | filing |
| 13 Feb 2025filed 18 Feb 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 | filing |
| 11 Dec 2023filed 12 Dec 2023 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 2 Mar 2023filed 2 Mar 2023 | Albireo Pharmaoption or derivative | SEC FORM 4 Code D | —15,900 | filing |
| 2 Mar 2023filed 2 Mar 2023 | Albireo Pharmaoption or derivative | SEC FORM 4 Code D | —10,063 | filing |
| 2 Mar 2023filed 2 Mar 2023 | Albireo Pharmaoption or derivative | SEC FORM 4 Code D | —24,337 | filing |
| 2 Mar 2023filed 2 Mar 2023 | Albireo Pharmaoption or derivative | SEC FORM 4 Code D | —23,700 | filing |
| 2 Mar 2023filed 2 Mar 2023 | Albireo Pharmaoption or derivative | SEC FORM 4 Code D | —37,500 | filing |
| 2 Mar 2023filed 2 Mar 2023 | Albireo Pharmaoption or derivative | SEC FORM 4 Code D | —65,850 | filing |
| 2 Mar 2023filed 2 Mar 2023 | Albireo Pharma | SEC FORM 4 Code U | —3,296 | filing |
| 23 Jan 2023filed 23 Jan 2023 | Albireo Pharma | SEC FORM 4 Sold | $9,986228 at $43.80 | filing |
News
No headline names them, or the companies they trade most, lately.